secwatch.observer — SEC 8-K summary
======================================

Issuer:     Penumbra Inc (PEN)
CIK:        0001321732
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001321732-26-000018
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Penumbra Q1 revenue $374.8M (+15.6% YoY); net income $32.6M; no guidance due to pending BSX acquisition
--------------------------------------------------------------------------------

- Revenue $374.8M, up 15.6% YoY; thrombectomy $253.9M (+12.1%), embolization & access $120.8M (+23.8%).
- Gross margin 67.6% (+1.0 pp); operating income $38.2M; net income $32.6M.
- Operating expenses include $9.4M acquisition-related costs for pending Boston Scientific deal.
- No FY2026 guidance provided due to pending acquisition by Boston Scientific (NYSE: BSX).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1321732/000132173226000018/0001321732-26-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1321732/000132173226000018/pen-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001321732-26-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer